Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone ophthalmic suspension for inflammation after cataract surgery
NCT03687931Phase 2Completed
- Sponsor
- iDrop Inc
- Start
- Aug 2018
- Primary completion
- Feb 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dexamethasone in ocular inflammation (2 arms), sponsored by iDrop Inc. Primary endpoint: Anterior Chamber Cell at 30 days. Started Aug 2018; status: completed.
02
Drugs
dexamethasone
03
Conditions
ocular inflammation
Beyond the preview
Go deeper on NCT03687931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03687931.